Company
Inomagen Therapeutics
Developing a non-viral disease-modifying gene therapy to improve the treatment of atrial fibrillation.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Chicago, United States
- Legal name
- Inomagen Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
At Inomagen, we are exclusively focused on discovering and developing transformative gene therapies to markedly improve the treatment of atrial fibrillation. Our scientific advancements have been the result of significant non-dilutive grant funding. The company has an exclusive license agreement with Northwestern University for a robust IP estate and has assembled a highly experienced team to bring our therapies to market.
Funding snapshot
- Total raised
- $540KSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $140K2025-06-05
Funding rounds
- Round, 2025
- $140K2025-06-05, SEC form D sold, 4 investors
- Round, 2024
- $200K2024-03-29, SEC form D sold, 4 investors
- Round, 2014
- $200K2014-11-12, SEC form D sold, 8 investors
Loading relationship preview